Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

This publication has 14 references indexed in Scilit:

• Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
  New England Journal of Medicine, 2018
• Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
  The Lancet, 2018
• Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
  The Lancet Oncology, 2018
• Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
  Journal of Clinical Oncology, 2017
• Postibrutinib outcomes in patients with mantle cell lymphoma
  Blood, 2016
• Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
  Annals of Oncology, 2015
• Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
  New England Journal of Medicine, 2013
• Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
  Journal of Clinical Oncology, 2009
• Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
  Annals of Oncology, 2008
• Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
  Blood, 2008